Scotland adopts NICE (UK National Institute for Clinical Excellence) guidance on PDT (photodynamic therapy):
This article was originally published in Clinica
NHS Quality Improvement Scotland has advised that guidance issued by the National Institute for Clinical Excellence (NICE) on the provision of photodynamic therapy for age-related macular degeneration is as valid for Scotland as for England and Wales. A Verteporfin Photodynamic Therapy Cohort Study developed by the Royal College of Ophthalmologists will be used, says the NHSQIS, to collect outcomes of the treatment of predominantly classic choroidal neovascularisation (CNV) and other clinical and cost-effectiveness data needed to inform future use of the technology. NHSScotland is considering how best to identify patients for treatment. NICE recommended researching the potential for population screening of the condition (see Clinica No 1076, p 6).